AZ chalks up another positive trial for hypertension drug
AstraZeneca’s baxdrostat has hit the mark in another phase 3 trial involving people who struggle to control their blood pressure with current therapies, keeping the would-be blockbuster on track for regulatory filings this year. The latest top-line readout from the Bax24 study in patients with resistant hypertension showed that baxdrostat achieved a statistically significant reduction…